Open replacement of heart valves (all valves)

Series
Cardiovascular
Status
Ongoing
Date
Number of report
048

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for open replacement of heart valves (aortic, mitral, tricuspid and pulmonary).

Report includes information about two types of prosthetic heart valves:

  • biological valves
  • mechanical prosthetic valves

Open replacement of heart valves will be analyzed in conjunction with open coronary artery bypass grafting (CABG).

The following indications will be considered:

  • Aortic stenosis
  • Mitral insufficiency
  • Tricuspid insufficiency
  • Pulmonary valve insufficiency

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

Manufacturers of devices for heart valves (for open or thoracoscopic placement, not percutaneous)

  • Abbott Vascular (Trifecta, SJM Regent, Epic™ Mitral)
  • CryoLife Life Technologies, Inc. (On-X)
  • Edwards Lifesciences (INSPIRIS RESILIA, EDWARDS INTUITY Elite, Carpentier-Edwards PERIMOUNT  Magna-Ease)
  • Labcor (Dokimos Plus)
  • Lepu Medical (GK-3)
  • LivaNova (Perceval, Crown PRT, Solo Smart, Mitroflow with PRT, Bicarbon Aortic Family, Carbomedic Aortic family)
  • Medtronic (Avalus Bioprosthesis, Hancock II, Hancock II Ultra, Mosaic, Mosaic Ultra, Freestyle, Open Pivot)
  • TTK Healthcare (Chitra)

Table of content is not available at the moment. Report is still ongoing.

There are no relevant news at the moment
(we accept only company emails)